Valuation: SIGA Technologies, Inc.

Market Cap 218M 195M 180M 163M 304M 20.71B 310M 2.14B 860M 10.89B 818M 801M 34.35B P/E 2026 *
60.8x
P/E 2027 * 2.81x
Enterprise Value 100M 89.58M 82.4M 74.66M 140M 9.5B 142M 983M 394M 5B 375M 367M 15.76B EV / Sales 2026 *
1.67x
EV / Sales 2027 * 0.43x
Free-Float
57.27%
Yield 2026 *
19.7%
Yield 2027 * 19.7%
1 day-4.40%
1 week-2.56%
Current month-10.59%
1 month-10.59%
3 months-6.46%
6 months-33.91%
Current year-50.25%
1 week 3.03
Extreme 3.03
3.33
1 month 3.03
Extreme 3.03
3.68
Current year 2.83
Extreme 2.83
7.1
1 year 2.83
Extreme 2.83
8.46
3 years 2.83
Extreme 2.83
12.83
5 years 2.83
Extreme 2.83
26.99
10 years 1.9
Extreme 1.9
26.99
Manager TitleAgeSince
Chief Executive Officer 54 27/01/2024
Director of Finance/CFO 55 10/02/2011
Chief Operating Officer - 01/01/2020
Director TitleAgeSince
Director/Board Member 73 11/03/2009
Director/Board Member 72 16/06/2020
Director/Board Member 42 10/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
25/03/26 Exercice

General Counsel

17,366 0.0243%
13/03/26 Exercice

General Counsel

121,769 0.1700%
13/03/26 Exercice

Chief Technology Officer

81,787 0.1142%
Change 5-day change 1-year change 3-year change Capi.($)
-4.40%-2.56%-63.42%-39.08% 228M
+3.19%+11.31%+67.86%+150.58% 1,224B
-0.73%+3.56%+44.51%+85.81% 662B
+1.41%+3.24%+29.22%+107.83% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.18%+2.93%+73.30%+45.62% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.15%+6.09%+59.59%+77.06% 249B
+3.06%+9.38%+44.11%+119.47% 205B
Average +1.12%+4.76%+35.59%+70.92% 417.71B
Weighted average by Cap. +1.17%+6.33%+50.90%+98.22%

Financials

2026 *2027 *
Net sales 59.86M 53.61M 49.32M 44.68M 83.53M 5.68B 85.09M 588M 236M 2.99B 225M 220M 9.43B 162M 145M 133M 121M 226M 15.39B 230M 1.59B 639M 8.09B 608M 595M 25.53B
Net income 3.72M 3.33M 3.06M 2.78M 5.19M 353M 5.29M 36.55M 14.67M 186M 13.96M 13.66M 586M 77.88M 69.75M 64.16M 58.14M 109M 7.4B 111M 765M 307M 3.89B 292M 286M 12.27B
Net Debt -118M -106M -97.24M -88.11M -165M -11.21B -168M -1.16B -466M -5.9B -443M -434M -18.59B -148M -132M -122M -110M -206M -14.05B -210M -1.45B -583M -7.39B -555M -543M -23.3B
Projected Income Statement - Annual - SIGA Technologies, Inc.
Logo SIGA Technologies, Inc.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Employees
49
Date Price Change Volume
30/10/26 $3.040 -4.40% 504,678
29/10/26 $3.180 -3.93% 495,002
28/10/26 $3.310 +3.44% 759,413
27/10/26 $3.200 +1.43% 409,255
26/10/26 $3.155 +1.12% 378,742
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - SIGA Technologies, Inc.

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SIGA Technologies, Inc.
  1. Stock Market
  2. Stocks
  3. SIGA Stock